Logo image
Back
Stiripentol use in Dravet syndrome patients in the USA: Results of a real-world study
Journal article   Open access   Peer reviewed

Stiripentol use in Dravet syndrome patients in the USA: Results of a real-world study

Elaine Wirrell, James Wheless, Michael Scott Perry, Linda Laux, Karen C Keough, Julie Ziobro, Aimee F Luat, Gewalin Aungaroon, Michael A Ciliberto, Roxane Noel, …
Epilepsia open, Vol.11(1), pp.200-210
02/2026
DOI: 10.1002/epi4.70191
PMCID: PMC12903828
PMID: 41321080
url
https://doi.org/10.1002/epi4.70191View
Published (Version of record) Open Access

Abstract

Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy with a high seizure burden and mortality risk. Stiripentol, one of the first DS-specific therapies, received FDA approval in 2018 but its real-world use and impact post-approval in the USA remain insufficiently characterized. The STIRUS study aimed to assess treatment patterns, clinical efficacy, and quality of life outcomes associated with stiripentol in a contemporary US cohort. STIRUS was a retrospective, multicenter chart review of 98 DS patients who initiated stiripentol after FDA approval and were treated for at least 3 months. Data were collected from 10 USA epilepsy centers on seizure types and frequency, status epilepticus (SE), rescue medication use, emergency room visits, and quality of life, at baseline and during the first and final 3 months on stiripentol. Changes over time were assessed using generalized estimating equation models. Initiation of stiripentol was associated with a significant reduction in bilateral convulsive seizure frequency (OR = 2.16, p < 0.006) and a nearly 50% decrease in SE episodes (OR = 2.9, p < 0.003). Importantly, there was a marked decline in rescue medication use and seizure-related hospital visits: the proportion of patients requiring no rescue medications increased from 23% to over 53%, and those needing frequent emergency interventions dropped from 39% at baseline to 14% during the final 3 months. Quality of life improved in more than half of patients and caregivers. The STIRUS study supports the real-world efficacy of stiripentol in reducing seizure burden and healthcare utilization in DS. Despite its demonstrated benefits and approval for use in infants, stiripentol remains underutilized and often introduced late in the treatment course. Early and broader adoption may help improve clinical outcomes and quality of life in this vulnerable population. The STIRUS study found that stiripentol, an anti-seizure medication specifically approved for Dravet Syndrome, helped reduce seizures and hospital visits for children living with this severe form of epilepsy. Patients had fewer convulsive seizures, needed fewer rescue medicines, and reported better quality of life. Despite these benefits, stiripentol is still not widely used and often started too late in treatment, suggesting earlier use could further improve outcomes.
 Quality of Life status epilepticus healthcare utilization stiripentol efficacy

Details

Metrics

1 Record Views
Logo image